<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675218</url>
  </required_header>
  <id_info>
    <org_study_id>1508203</org_study_id>
    <secondary_id>2015‐005644‐33</secondary_id>
    <nct_id>NCT02675218</nct_id>
  </id_info>
  <brief_title>Bone MicroArchitecture Abatacept (BMA2)</brief_title>
  <acronym>BMA2</acronym>
  <official_title>Bone MicroArchitecture Abatacept in Rheumatoid Arthritis Patients (BMA2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid Arthritis patients management reposes primarily on the use of disease-modifying
      antirheumatic drugs (DMARDs).

      Among DMARDs available in 2015, researchers demonstrated the ability to reduce synovitis,
      biomarkers of inflammation, and bone destruction.

      Given the demonstration of correlation between joint inflammation and structural progression
      at each joint level as well as the opportunity for bone remodeling with resolution of joint
      inflammation, researchers expect to observe an improvement in bone micro-architecture
      parameters specifically in rheumatoid arthritis patients without remaining joint inflammation
      3 months following abatacept treatment initiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid Arthritis patients management reposes primarily on the use of disease-modifying
      anti-rheumatic drugs. In patients responding insufficiently to Methotrexate, and/or other
      disease-modifying anti-rheumatic drugs (DMARD) strategies, with or without glucocorticoids,
      biological DMARD (TNF inhibitors, abatacept or tocilizumab, and, under certain circumstances,
      rituximab) should be commenced with Methotrexate. Among DMARD available in 2015, abatacept
      has demonstrated the ability to reduce synovitis, biomarkers of inflammation, and bone
      destruction. Monitoring rheumatoid arthritis patients after starting abatacept by US exams
      observed a strong reduction of power Doppler ultra-sonography at 3 months in two third of
      patients.

      Given the demonstration of correlation between joint inflammation and structural progression
      at each joint level as well as the opportunity for bone remodeling with resolution of joint
      inflammation, researchers expect to observe an improvement in bone micro-architecture
      parameters specifically in rheumatoid arthritis patients without remaining joint inflammation
      3 months following abatacept initiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Value of joint inflammation</measure>
    <time_frame>1 year</time_frame>
    <description>The predictive value of persistent joint inflammation on volumetric trabecular bone density is measured by high resolution pQCT (peripheral Quantitative Computed Tomography) after 1 year treatment with Abatacept.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis.</arm_group_label>
    <description>Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with rheumatoid arthritis</intervention_name>
    <description>Doppler effect at 3 months after Abatacept treatment initiation.</description>
    <arm_group_label>Patients with rheumatoid arthritis.</arm_group_label>
    <other_name>Doppler effect</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be performed to determine the predictive value of joint inflammation.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis patients diagnosed according to ACR/EULAR 2010 criteria, and Abatacept
        therapy sub-cutaneous required according EULAR recommendation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent form,

          -  Age ≥ 18 years,

          -  Rheumatoid arthritis diagnosis according to ACR/EULAR 2010 criteria

          -  Abatacept therapy sub-cutaneous required according EULAR recommendations

          -  Patients affiliated to health insurance

        Exclusion Criteria:

          -  Other arthritis than rheumatoid arthritis,

          -  Contraindication to abatacept,

          -  Concomitant treatment with zoledronic acid (Aclasta®) or denosumab (Prolia®),

          -  Injection intravenously or intra-articular at the 2nd and 3rd metacarpophalangeal
             joint of the dominant hand during the 3 months prior to inclusion,

          -  Prior or planned joint surgery at the 2nd or 3rd metacarpophalangeal joint of the
             dominant hand over the one year study,

          -  No recent used of high density contrast material,

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert MAROTTE, PhD</last_name>
    <email>hubert.marotte@univ-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON, CRA</last_name>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Édouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charline-Lucie ESTUBLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roland CHAPURLAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charline-Lucie ESTUBLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Regional D'Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric LESPESSAILLES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric LESPESSAILLES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie LOISEAU PERES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine SALLIOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie DUCOURAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique-Hopitaux de Paris</name>
      <address>
        <city>Paris 04</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martine COHEN-SOLAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martine COHEN-SOLAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert MAROTTE, PhD</last_name>
      <email>hubert.marotte@univ-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert MAROTTE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain CANTAGREL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain CANTAGREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bénédicte JAMARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud CONSTANTIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel LAROCHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

